Loading the company…
Loading the company…
Files annual reports on Form 20-F; half-year results are not in XBRL, so only full years are shown. Families: Debridement & negative-pressure wound therapy, Cholecystectomy & appendectomy, Skin substitutes & wound grafts, Lumbar fusion, Hysterectomy, hysteroscopy & ablation, Kyphoplasty & vertebroplasty, Cervical fusion & disc arthroplasty, Ear tubes & middle ear surgery, Radiofrequency ablation (facet, genicular, basivertebral), Bone graft & orthobiologics, Hernia repair, Bronchoscopy & lung nodule and 4 more.
All companies · Product and company coverage
The same products and surgeons under a new company (Smith+Nephew): expect new reps and contracts, and ask what changed for them.
Source · closing date to confirm
Payments and FDA records read by the company that owns the business today, so a deal never looks like surgeons switching; a surgeon’s payment history still shows the name each payment was made under.
In the last ten years FDA made 137 decisions for Smith+Nephew (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 12 procedure families, the most in 2018 (21). The latest was on 2026-09-11.
| Date | Kind | Number | Device |
|---|---|---|---|
| 2026-09-11 | 510(k) | K261338 | RENASYS DYNAFLOW Kit (66807741) |
| 2026-09-08 | 510(k) | K261462 | LANDMARK Total Knee System |
| 2026-07-09 | 510(k) | K261968 | Q-FIX KNOTLESS All-Suture Anchor, 2.8mm, with one black knotless and one blue MINITAPE suture (72205981); Q-FIX KNOTLESS All-Suture Anchor, 2.8mm, with one blue knotless and one black MINITAPE suture (72205982) |
| 2026-05-27 | 510(k) | K260646 | RENASYS EDGE (66803126) |
| 2026-04-06 | 510(k) | K254084 | AETOS Shoulder System - CONCELOC Glenoids |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Smith+Nephew.
In 2025, Smith+Nephew reported engagement with 14,829 surgeons and other clinicians in the states MedaRep covers, worth $15M in consulting, speaking, meals and travel for its device products, the most in Florida ($1.4M to 1,474). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Florida ($1.4M, 1,474 engaged), California ($1.4M, 1,273 engaged), New York ($1.3M, 834 engaged), North Carolina ($1.3M, 542 engaged), Illinois ($1.0M, 372 engaged).